The issue is that the B-ARM with low PD-L1 expression only had an MOS of around 1.4 months better than the D-ARM with low PD-L1 expression. So all Peregrine is doing is massaging the data output to make the B-ARM seem much better than it is.
So why is PPHM comparing the MOS of Low PD-L1 versus High PD-L1 instead of comparing it against the D-P arm?
What about the bavi patients who went on to receive a I-O drug that have yet to reach an MOS vs. 12.1 months. How many patients were there in this group? Is there no promising combo there?
Market Data 
Markets 
AI
